No description available.

No description available.

A model of acute glutamate- and domoate-induced toxicity was developed and characterized in cultured rat cerebellar granule cells (CGCs) using experimental conditions which preserve the voltage-dependency of NMDA receptor function. Glutamate, which is normally non-toxic to CGCs in physiologic media (pH 7.4), was shown to induce a cytotoxic response after 2 hours when the exposure temperature was reduced from 37�� to 22��. Pharmacological characterization of this response demonstrated that cytotoxicity is mediated by the activation of NMDA receptors, while non-NMDA receptors produce a depolarizing stimulus that enhances release of the voltage-dependent Mg����� blockade of NMDA receptor ion channels. Reduced temperature was shown to facilitate NMDA receptor activation by compromising the ability of CGCs to maintain normal electrochemical gradients during glutamate-induced ion flux. When compared to glutamate, the non-NMDA receptor agonist, domoate, demonstrated an acute cytotoxic response in CGCs that was also mediated predominantly by NMDA receptors. NMDA receptor activation was produced secondary to a domoateinduced release of glutamate and aspartate from CGCs; therefore, domoate synergistically potentiates glutamate/aspartate-mediated neurotoxicity. Domoate-induced excitatory amino acid (EAA) release was investigated and found to occur almost exclusively through reversal of the high affinity Na+-coupled glutamate transporter and by osmoregulatory mechanisms. CGCs also responded to domoate-induced depolarization by releasing adenosine which suppresses exocytotic EAA release through A1 receptor activation. The functional and pharmacological characteristics of NMDA receptors were characterized in 12 DIC CGCs using the channel blocking compound [��H]MK-801 (dizocilpine). Kinetic analysis of [��H]MK-801 binding indicated the possible existence of at least two NMDA receptor populations on 12 DIC CGC membranes, and the equilibrium competition binding of MK-801 and other channel blocking compounds was consistent with the presence of high and low affinity binding sites. The neuroprotective potencies of NMDA receptor channel blockers correlated significantly with their affinities for the NMDA receptor derived from equilibrium competition analysis of [��H]MK-801 high-affinity binding. Thus, whereas 12 DIC CGCs express a pharmacologically heterogeneous population of NMDA receptors, it is the high-affinity component of [��H]MK-801 binding that mediates glutamate toxicity. / Graduation date: 1998

Thesis (Ph.D.) -- University of Montana, 2008. / Title from author supplied metadata. Description based on contents viewed on July 15, 2009. Includes bibliographical references.

Abstract not available

Thesis (Ph. D.)--Ohio State University, 2007. / Title from first page of PDF file. Includes bibliographical references (p. 140-158).

Thesis (Ph. D.)--University of Montana, 2007. / Title from title screen Description based on contents viewed Oct. 12, 2007. Includes bibliographical references (p. 151-177).

The amino acid, 6-hydroxydopa (6-OHDOPA), found at the active site of amine oxidases, exists as a keto-enol. Exogenously administered 6-OHDOPA is an excitotoxin like β-N-oxalylamino-L-alanine (BOAA) and β-N-methylamino-L-alanine (BMAA), acting at the non-N-methyl-D-aspartate (non-NMDA) α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor. BMAA and BOAA are causal factors of neurolathyrism in humans. Much exogenously administered 6-OHDOPA is biotransformed by aminoacid decarboxylase (AADC) to the highly potent and catecholamine-(CA) selective neurotoxin, 6-hydroxydopamine (6-OHDA). 6-OHDOPA destroys locus coeruleus noradrenergic perikarya and produces associated denervation of brain by norepinephrine-(NE) containing fibers. Opiopeptides and opioids enhance neurotoxic effects of 6-OHDOPA on noradrenergic nerves, by a naloxone-reversible process. An understanding of mechanisms underlying neurotoxic effects of 6-OHDOPA can be helpful in defining actions of known and newfound amino acids and for investigating their potential neurotoxic properties.

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

PURPOSE: To review the role of excitatory neurotransmitters in normal mammalian brain function, the concept of excitotoxic neuronal death as an important final common path in a variety of diseases, and modification of excitatory synaptic transmission as an important new pharmacological principle. These principles are discussed, with special emphasis on diseases of importance to older adults. DATA SOURCES: A MEDLINE search from 1966 to May 1995 was undertaken, as well as a manual search of current issues of clinical and basic neuroscience journals, for articles that addressed glutamate N-methyl-D-aspartate and/or excitotoxicity. STUDY SELECTION: A total of 5398 original and 68 review articles were identified that addressed animal and human experimentation relevant to excitotoxic neuronal death. There were 364 articles with potential significance for clinical application identified; 132 of the most recent references are provided. DATA EXTRACTION: All articles were classified into three categories: general receptor, biology pathogenesis of disease, and pharmacotherapy. RESULTS: Glutamic and aspartic acids are the physiological mediators of most excitatory synaptic transmission. This is critical to several normal nervous system functions, including memory and long-term modification of synaptic transmission and nociception. Activation of the inotropic NMDA and non-NMDA receptors increases transmembrane calcium and sodium fluxes, and the metabotropic glutamate receptor activation results in generation of inositol triphosphate and inhibition of adenylate cyclase. Numerous modulatory sites exist, especially on the NMDA receptor. Nitric oxide, arachidonic acid, superoxide, and intracellular calcium overload are the ultimate mediators of neuronal death. Glutamate re-uptake transporters belong to a unique family of amino acid transport systems, the malfunction of which is intricately involved in disease pathogenesis. Ischemic stroke, hypoglycemia, Parkinson's disease, alcohol intoxication and withdrawal, Alzheimer's disease, epilepsy, and chronic pain syndromes are only some of the important clinical neurological disorders with a major pathogenic role for the excitatory amino acids. CONCLUSIONS: Pharmacological manipulation of the excitatory amino acid receptors is likely to be of benefit in important and common diseases of the nervous system. Only a few of the currently available drugs that modify excitatory neurotransmission, such as remacemide, lamotrigine, and tizanidine, have an acceptable therapeutic index. The identification of numerous receptor subtypes, topographic variabilities of distribution, and multiple modulatory sites will provide a true challenge to the neuropharmacologist.